Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170483 | 0.78 | CCR4 (0.43) | CD274PDCD1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL13745097 | 0.78 | PIK3CA (0.35) | CDK2P2RX3P2RX2MAPTCASP1 | |
| SCHEMBL26281254 | 0.77 | CCR4 (0.41) | CD274PDCD1CYP1A2KDM4EALDH1A1 | |
| SCHEMBL12767704 | 0.77 | PIK3CA (0.41) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL11222083 | 0.77 | POLB (0.36) | CD274PDCD1MAPTCYP1A2KDM4E | |
| SCHEMBL31652200 | 0.77 | CCR4 (0.41) | CD274PDCD1CYP1A2KDM4EALDH1A1 | |
| SCHEMBL14612841 | 0.75 | ALOX5AP (0.38) | P2RX3P2RX2MAPTCASP1AURKA | |
| SCHEMBL30415101 | 0.75 | CCR4 (0.47) | — | |
| SCHEMBL12726916 | 0.73 | PDCD1 (0.41) | CD274PDCD1CDK2P2RX3P2RX2 | |
| SCHEMBL24193107 | 0.73 | PDCD1 (0.33) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-12071424-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| CN-111566089-B | IRE1 small molecule inhibitors | 康奈尔大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-10745379-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745379-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200157079-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| EP-3630748-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20190169160-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20190169160-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20180346446-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2018-12-06 | — | — | US | disclosed |
| WO-2018222918-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| WO-2004108711-A1 | PYRAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108703-A1 | PYRAZINYL 3-CYANOQUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
| US-20200157079-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
| US-12071424-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | CD274 4182/4885PDCD1 3338/4885CDK2 3836/4885 |
| US-11649224-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
| US-20180346446-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
| US-20190169160-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
| US-10745379-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CD274 2585/4885PDCD1 961/4885CDK2 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.